BIBR 1087 SE is an intermediate metabolite of dabigatran etexilate.
[1]. Stangier J, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008 Dec;48(12):1411-9.
















